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In our presented research, wemade an attempt to predict the 3Dmodel for cysteine synthase (A2GMG5 TRIVA) using homology-
modeling approaches. To investigate deeper into the predicted structure, we further performed a molecular dynamics simulation
for 10 ns and calculated several supporting analysis for structural properties such as RMSF, radius of gyration, and the total energy
calculation to support the predicted structuredmodel of cysteine synthase.Thepresent findings led us to conclude that the proposed
model is stereochemically stable. The overall PROCHECK G factor for the homology-modeled structure was −0.04. On the basis
of the virtual screening for cysteine synthase against the NCI subset II molecule, we present the molecule 1-N, 4-N-bis [3-(1H-
benzimidazol-2-yl) phenyl] benzene-1,4-dicarboxamide (ZINC01690699) having theminimumenergy score (−13.0 Kcal/Mol) and
a log P value of 6 as a potential inhibitory molecule used to inhibit the growth of T. vaginalis infection.
1. Introduction
Trichomoniasis has been described as an infection of the
urogenital tract; mainly urethra and the vagina are the most
common sites of infection in women whereas the urinary
tract is the primary site of infection in men. It has been
previously reported that the infection usually does not cause
symptoms in men [1]. Globally, Trichomonas vaginalis is the
most prevalent nonviral sexually transmitted infection as
per the proposed reports [2, 3]. Since the discovery of the
casual agent for the T. vaginalis in 1836 [4] and its wide
spread infection in women since 1916, several treatments
have been made available as a possible medication to control
the widespread nonviral transmission. Earlier, metronidazole
(1957) was proposed to be the available treatment to which
T. vaginalis acquired drug resistance in 1962 [5]. Several
studies document the fact that it acquires cross-resistance
between different nitroimidazoles [6, 7]. Metronidazole is a
prodrug, which needs to be activated by enzymes prior to
its action on the desired target. In metronidazole-resistant
T. vaginalis, it was observed that the expression levels of the
hydrogenosomal enzymes pyruvate ferredoxin oxidoreduc-
tase, ferrodoxin, malic enzyme, and hydrogenase were found
to be significantly low, which might probably eliminate the
ability of the parasite to activate metronidazole [8, 9]. Devel-
opment of multidrug resistance strongly justifies the need of
the identification of drug targets in T. vaginalis, which is a
major challenge in modern medicine. With the development
of the molecular simulation approaches, novel drug targets
of immense potential can be easily identified and can be
used as lead molecules for the development of new drug
targeted strategies. In order to approach the defense against
the protozoan parasite, differences in biochemical mech-
anisms between parasite and host can suggest promising
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drug targets without expected cytotoxicity towards the
human host. A sequencing effort in 2007 by The Institute of
Genomic Research (TIGR) led to the first reports on the draft
genome sequence of T. vaginalis, which presented us with an
open source sequence to look for the wide variations, drug
target identification and to hypothesize an effective measure
for the effective treatment of the T. vaginalis [10].
In the presented research, we aim to concentrate on three
hypotheses to postulate the novel drug target for trichomoni-
asis: (1) to predict the structural model of cysteine synthase,
(2) to investigate structural analysis of cysteine synthase using
molecular dynamics simulation studies, and (3) to perform
virtual screening and docking to identify inhibitor molecules
against the suitable ligand. We observed the stable RMSD
just after 1 ns time scale. Furthermore, we screened out ten
possible ligand molecules after virtual screening of a library
of ligands.We found that the ligandZINC01690699hasmin-
imum energy score in comparison to the rest of molecules,
which have almost the same energy score profile. We demon-
strated through our results that ZINC01690699 showed the
most stable hydrogen and hydrophobic interactions with the
active site residue as per the Ligplot analysis. We further
validated the binding affinity of screened molecules and
natural substrate of cysteine synthase using in silico docking
studies. We conclude that the molecule 1-N, 4-N-bis [3-
(1H-benzimidazol-2-yl) phenyl] benzene-1, 4-dicarboxamide
(ZINC01690699) is proposed to be a potential inhibitor for
cysteine synthase. ZINC01690699 can be further validated
for inhibition ofT. vaginalis by experimental procedures. Our
study postulates an important ligand of potential importance
for the development of the remedial approaches for the
treatment of the T. vaginalis infection.
2. Materials and Methods
2.1. Selection of the Drug Target. T. vaginalis is an anaerobic
protozoan parasite of humans, which lacks glutathione and
relies heavily on cysteine usage as a major redox buffer for
the synthesis of the cysteine, a potential molecule of thiol
metabolism from sulfide [11–15]. It has been demonstrated
earlier that cysteine synthase can be potentially exploited for
drug target identification and several drug targets have been
identified [11–13].Themetabolic pathway analysis on the pos-
sible novel drug target in T. vaginalis suggested several drug
targets, which can be exploited for the inhibitor designing.
Since cysteine synthase is absent in human; therefore, in the
present study, we have selected cysteine synthase as the most
promising drug target for the evaluation of the molecular
dynamics simulations.
2.2. Model Generation of the Selected Drug Target. For puta-
tivemodel generation,we retrieved the cysteine synthase (tar-
get) amino acid sequence from Uniprot (A2GMG5 TRIVA)
(http://www.expasy.org) [16]. We found that there is no
three-dimensional structure (3D) available for the protein
in Protein Data Bank (PDB); hence, we made an attempt
to postulate the putative 3D model of the cysteine synthase.
To infer the model, we performed BLASTP [17] searches
against Brookhaven Protein Data Bank (PDB) [18] with
default parameters to find suitable templates for homology
modeling. Based on the criteria of maximum identity with
high score and lower e-value, crystal structure having PDB
ID 2BHSwas selected as the template for further downstream
processing. We observed that the sequence identity and
similarity between the target and putative template were
44% and 65%, respectively. Sequence characteristics showed
that the target sequence is 299 whereas the template is 303
amino acids long, giving the acceptable query coverage of
97% during the sequence alignment.The sequence alignment
of cysteine synthase and the template 2BHS was carried out
using theCLUSTALW[19] (http://www.ebi.ac.uk/Tools/msa/
clustalw2/) program.
In order to generate the model MODELLER9v6 (http://
www.salilab.org/modeller) was used for 3D structure gen-
eration based on the obtained information from sequence
alignment [20].TheMODELLER software employs probabil-
ity density functions (PDFs) as the spatial restraints rather
than energy [21, 22]. We generated the 3D model of the
protein by optimization of the molecular PDFs such that the
model violates the input restraints as possible. The molecular
PDF was derived as a combination of PDFs restraining
individual spatial features of the whole molecule. In our
study, MODELLER generated 20 models. The model having
the best G-score of PROCHECK [23] and with the best
VERIFY3D [24] profile was further subjected to energy
minimization. VERIFY3D (a structure evaluation server) was
used to check the residue profiles of the obtained 3D models.
In order to assess the stereochemical qualities of the 3D
models, PROCHECK analysis was again performed. Quality
evaluation of the model for the environment profile was also
predicted using ERRAT (structure evaluation server available
at http://nihserver.mbi.ucla.edu/ERRATv2/ [25]). The final
refined model was evaluated for its atomic contacts using
the WhatIF program [26] to identify the bad packing of side
chain atoms or unusual residue contacts.Thepredictedmodel
was also analysed for error recognition in three-dimensional
structure by using ProSA web server [27, 28].This model was
further subjected for the active site identification, molecular
dynamics simulations, and docking analysis.
2.3. Molecular Dynamics Simulation Study of the Predicted
Model. In our study, we performed molecular dynamics
(MD) simulations ofmodeled cysteine synthase protein using
GROMACS 4.0.6 software package [29] with GROMOS 96
force field [30] and the flexible SPC water model. The initial
structure was immersed in a periodic water box of cubic
shape (0.5 nm thick). Electrostatic energy was calculated
using the particle mesh Ewald method, which permits the
use of Ewald summation at a computational cost comparable
to that of a simple truncation method of 10 A˚ or less [31].
We retained the cutoff distance as 1.0 nm for the calculation
of the coulomb and Van der Waal’s interaction, respectively.
After energy minimization using a steepest descent for 1000
steps, the system was subjected to equilibration at 300 k and
normal pressure for 100 ps under the conditions of position
restraints for heavy atoms. We subsequently applied LINCS
[32] constraints for all bonds, keeping the whole protein
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Figure 1: (a) Predicted model of cysteine synthase complexed with ligand ZINC01690699. Cysteine synthase is represented in cartoon
drawing and ligand in stick form. (b) Modeled cysteine synthase complexed with its best-identified inhibitor ZINC01690699 in docked
form.
Figure 2: Modeled cysteine synthase complexed with its natural
substrate.
molecule fixed and allowing only the water molecule to
move to equilibrate with respect to the protein structure.The
system was coupled to the external bath by the Berendsen
pressure and temperature coupling [33]. The final MD calcu-
lations were performed for 10 ns under the same conditions
except that the position restraints were removed. The results
were analyzed using the standard software provided by
the GROMACS package. An average structure was further
refined using a steepest descent energy minimization.
2.4. Virtual Screening for Validated Model Structure and
Ligplot Analysis for Interaction Study. We further performed
virtual screening against the NCI subset II molecules
retrieved from ZINC database (http://zinc.docking.org) in
order to validate the developed molecular structure of
cysteine synthase using Autodock Vina (http://vina.scripps.
edu/) [34]. In total, 1,364 molecules from the NCI diversity
subset II (http://zinc.docking.org/) [35] were screened for
the cysteine synthase. Active sites were identified using
Putative Active Sites with Spheres (PASS; http://www.ccl.net/
cca/software/UNIX/pass/overview.shtml), which uses geom-
etry to characterize regions of buried volume in proteins and
to identify positions likely to represent binding sites based
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Figure 3: Z-score calculated for predicted model of cysteine
synthase by PROSA.
upon the size, shape, and burial extent of these volumes.
To analyze the docking results, python scripts in MGL tools
package were used for visualization. The ten ligands selected
based on the energy score after virtual screening were further
analyzed by Ligplot program to illustrate the hydrogen and
hydrophobic interactions between the ligand and active site
residue [36].
3. Results and Discussion
Trichomonas vaginalis, having anerobic carbohydrate metab-
olism and devoid of typical mitochondria, is the causative
agent of human trichomoniasis [37], a very common sexually
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transmitted infection with an estimated 170 million cases
occurring each year [38], that has been implicated as a major
risk factor in predisposition to human immunodeficiency
virus/AIDS [39]. The parasite itself is an unusual protozoan
that may be one of the earliest branching organisms [40, 41].
It is adapted to an environment containing only low oxy-
gen concentrations by being a fundamentally fermentative
organism, with oxygen apparently not making a significant
contribution to energy metabolism [42].
3.1. Prediction and ValidatedModeled Structure of the Cysteine
Synthase. In our presented study, we validated the predicted
model of cysteine synthase using different validation tools
and approaches. Firstly, we evaluated the structure using
the Ramachandran plot, and subsequently the structure was
analyzed using PROCHECK. We observed that the phi/psi
angles of the majority of the residues (92.9%) are present in
the most favored regions, followed by 5.5% residues, which
were present in the additional allowed regions, whereas 1.2%
and 0.4% residues were present in the generously allowed
region and in the disallowed regions, respectively.Thepresent
findings led us to conclude that the proposed model is
stereochemically stable.The overall PROCHECKG factor for
the homology-modeled structure was −0.04. We observed a
decrease in the overall G factor after MD simulation, which
indicates that there might be an increase in the number
of the bad dihedral angles of the modeled structure, which
might be possibly due to the MD simulation resulting in an
unfavorable dihedral angle, allowing the protein to overcome
high-energy barriers. We finally verified the structure using
the ERRATgraph estimated using the ERRAT,which analyses
the statistics of nonbonded interactions between different
atom types. It also gives an estimate of the error value, which
is calibrated to estimate the confidence limits of the validated
model [25].
We observed a quality factor of 73.592 for the predicted
model, which is an indication of the good quality model, as
earlier it has been described that models having the quality
scores of above 50 are considered as good quality predicted
model. The energetic architecture as predicted by PROSA,
which gives an estimation of the determination of the native
protein fold score, was negative (−9.06) for the modeled
protein. The observed value was close to that of template
fold score (−9.04), which is a further confirmation of the
reliability and stability of the proposed model (Figures 3 and
4). To be accurate in model prediction of cysteine synthase,
we further confirmed the model using VERIFY 3D server
and WHAT CHECK. We observed that 80.55% of residues
of modeled protein showed a score higher than 0.2, which is
a satisfactory 3D-1D score for the residues. On the basis of the
above stringent confirmatory tests, we postulate the putative
model for the cysteine synthase, which was further used for
the virtual screening of the potential inhibitors for cysteine
synthase.
The natural substrate, O-acetyl-L-serine, and selected
inhibitor molecules after the initial screening were docked
with Audodock Vina on cysteine synthase, and structural
analysis was conducted as shown in Figure 2. Audodock
Vina treats docking as a stochastic global optimization of
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Figure 4: Energy calculated for predicted model of cysteine syn-
thase by PROSA.
the scoring function and precalculating grid maps and pre-
calculates the interaction between every atom type pair at
every distance. We observed that the docked energy score of
cysteine synthase complexed with its best-selected inhibitor
molecule ZINC01690699 (1-N,4-N-bis[3-(1H-benzimid-
azol-2-yl)phenyl]benzene-1,4-dicarboxamide) having a
molecular weight of 548.606 g/mol was found to be signif-
icantly lower (−13.0 Kcal/Mol) as compared to the docked
energy score (−5.7 Kcal/Mol) of natural substrate complexed
with cysteine synthase (Figures 1(a) and 1(b)). We further
evaluated Z-score for the overall quality calibration of the
model. All the Z-scores of the experimentally determined
protein chains in current PDB were plotted (Figure 3). In this
plot, groups of structures from different sources (X-ray,
NMR) are distinguished using different colors where dark
blue represents NMR and light blue represents X-ray scores,
respectively. The Z-score of the predicted cysteine synthase
model was found to be within the range of scores, which are
typically predicted for native proteins of similar size (https://
prosa.services.came.sbg.ac.at/prosa help.html#output). The
energy plot of the predicted model showed local model
quality as visualized by plotting energies as a function of
amino acid sequence position (Figure 4). We found that the
calculated energy for the predicted model of cysteine
synthase was negative, which indicates an error free model of
the cysteine synthase as positive values correspond to
problematic or erroneous parts of the input structure (https://
prosa.services.came.sbg.ac.at/prosa help.html#output).
3.2. Molecular Dynamic Simulation of Cysteine Synthase. In
our study, the predicted model of cysteine synthase has
shown good accuracy of the structure as revealed by the
virtual screening. It has been earlier described that the virtual
BioMed Research International 5
0 2000 4000 6000 8000 10000
Time (ps)
Total energy
Gromacs energies
−3.58e+05
−3.57e+05
−3.56e+05
−3.55e+05
−3.54e+05
−3.53e+05
−3.52e+05
−3.51e+05
E
(k
J m
ol
−
1
)
Figure 5: Energy of the molecule during simulation at 10 ns.
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Figure 6: Modeled radius of gyration at 10 ns.
screened model should have the stable molecular dynamic
behavior.We evaluated the virtual screenedmodel of cysteine
synthase using the molecular dynamic stability criteria by
performing the molecular dynamic simulation study using
GROMACS 4.0.6 software package. In our case, molecular
dynamics simulation study revealed a consistent value of
the energy of the molecule throughout the time period of
simulation, which is an indication of strong basis of the fact
that the molecule has a stable structure as required for the
virtual screening and drug designing processes (Figure 5).
We further evaluated the radius of gyration parameter, and
it was observed that initially the radius of gyration was
increasing, but after 4000 ps it decreases up to 8000 ps and
finally become almost constant for the rest of the duration of
the simulation (Figure 6). This observation suggests and is in
line with the argument that the cysteine synthase model has
a compact structure, which provides the required stability to
the molecule and supports our previous molecular dynamic
simulations results. Rootmean square deviation (RMSD)was
evaluated during the simulation, and it was observed that it
was increasing in the beginning, but after 2000 ps it became
almost constant for the rest of the duration of the simulation,
which suggests that the hypothesized cysteine synthasemodel
has lesser RMSD for the cysteine synthase backbone and
has less flexibility, indicating the stable dynamic behavior
structure of cysteine synthase (Figure 7). It was observed that
the fluctuations in the rootmean square (RMS) were very low
and most of the atoms were free from the RMS fluctuations
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Figure 7: RMSD of modeled structure at 10 ns.
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(Figure 8). Furthermore, there were only few atoms, which
showed RMS fluctuation at C andN terminals due to the loop
region, which strongly suggests that cysteine synthase model
has an accurate and stable structure and can be used for the
virtual screening.
3.3. Virtual Screening. We performed virtual screening of
cysteine synthase against the NCI subset II of the ZINC
database. The entire top ten molecule hits having the mini-
mum energy were further screened out as the possible inhibi-
tor of the cysteine synthase as shown in Table 1. All the select-
ed molecules have very low energy score (below −11.0 Kcal/
Mol) as compared to the energy score of natural substrate
with cysteine synthase (−5.7 Kcal/Mol). We observed
that three ligands (ZINC29590263, ZINC29590259, and
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Figure 9: (a) Ligplot for screened ligand ZINC01690699. (b) Ligplot for screened ligand ZINC29590263. (c) Ligplot for screened ligand
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ZINC04783229) possess the same energy score (−11.5 Kcal/
Mol) whereas ligands ZINC13152284, ZINC18055497
(−11.0 Kcal/Mol) ZINC01568793, and ZINC01736227 have
nearly the same energy score (−11.1 Kcal/Mol). On the basis
of the above criteria, we evaluated the interaction kinetics of
the observed possible inhibitors. The Ligplot study revealed
that among the screened ligands ZINC01690699 had 12
hydrophobic and 4 hydrogen bond interactions (Figure 9(a)),
which is the highest in comparison with the number of
interactions as compared to the rest of the molecules
(Table 1). On the basis of the high occurrence of the
hydrophobic and hydrogen bond interactions, we selected
ZINC01690699 as the possible inhibitor lead molecule
as it has minimum energy score and highest number of
interactions with the active site residue of the cysteine
synthase; as most stable complex molecule as depicted in
the interaction profiles between the cysteine synthase and
the top five ligands according to the energy score (Figures
9(a) to 9(e) and Figure 10; Table 2). Structure analysis of
ZINC01690699 revealed that it has four hydrogen bonds,
which include one bond with each Thr 67 and Thr 175 and
two with Ser 64, and twelve hydrophobic bonds, which
include Val 35, Ile 39, Thr 63, Gly 65, Met 86, Gly 89, Val 90,
Thr 114, Ala 169, Thr 172, Leu 275, and Ala 277, respectively.
Another probable candidate ZINC29590263 has seven
hydrogen bonds for interaction at sites Asn 66, Thr 67, Thr
114, His 147, and Thr 175, respectively. Furthermore, it has
eight hydrophobic bonds with amino acids like Val 35, Ile
39, Ala 169, Thr 172, Pro 197, Tyr 202, Lys 207, and Ala
277 (Figure 9(b)). Interaction kinetics of ZINC29590259
revealed that it has six hydrogen bond interactions with
different amino acids at sites Thr 67, His 147, Thr 175, and
Leu 206 (Figure 9(c)) whereas total hydrophobic interactions
were eight, which include interactions at Val 35, Ile 39, Ala
169, Thr 172, Pro 197, Tyr 202, Lys 207, and Ala 277. We
observed that ZINC04783229 has only one hydrogen bond
with Gln 204 whereas it has eleven hydrophobic interactions
with different amino acids at sites Val 35, Gly 65, Thr 63, Asn
66,Met 86,Thr 114, Ala 169,Thr 172, Gly 205, Leu 275, andAla
277, respectively (Figure 9(d)). Another proposed inhibitor
ZINC29590257 has seven hydrogen bonds at Thr 63, Thr 67,
Thr 114,Thr 175, and Leu 206 coupled with eight hydrophobic
interactions (Val 35, Lys 36, Ile 39, Phe 138, Thr 172, Pro 197,
Lys 207, and Ala 277), respectively (Figure 9(e)). Interaction
sites of natural substrate O-acetyl-L-serine revealed that it
has seven hydrogen bonds with His 147, Ala 169, Gly 171, Thr
172, Ser 173, and Thr 175 and two hydrophobic interactions
with Val 35 and Ile 39 (Figure 10). Correlation coefficient
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Table 1: Molecules from NCI subset II of the ZINC database after virtual screening.
S. no.
ZINC ID of the
screened
molecules
IUPAC Convention of the ligand
Energy
score
Kcal/Mol
Hydrogen
bond Hydrophobic Molecularweight
(g/mol)
Log P value
Interaction of ligand with
active site residues
1 ZINC01690699 1-N,4-N-bis[3-(1H-benzimidazol-2-yl)phenyl]benzene-1,4-dicarboxamide −13 4 12 548.59336 6
2 ZINC29590263
8-chloro-7-[(2R,3R,4R,5S)-3-hydroxy-5-
methoxy-6,
6-dimethyl-4-(5-methyl-1H-pyrrole-2-
carbonyl)oxyoxan-2-yl]oxy-3-[[4-
hydroxy-3-(3-methylbut-2-
enyl)benzoyl]amino]-4-oxochromen-2-
olate
−11.5 7 8 696.12014 6.1
3 ZINC29590259
8-chloro-7-[(2R,3R,4S,5S)-3-hydroxy-5-
methoxy-6,6-dimethyl-4-(5-methyl-1H-
pyrrole-2-carbonyl)oxyoxan-2-yl]oxy-3-
[[4-hydroxy-3-(3-methylbut-2-
enyl)benzoyl]amino]-4-oxochromen-2-
olate
−11.5 6 8 696.12014 6.1
4 ZINC04783229 1-N,4-N-bis(3-phenylphenyl)piperazine-1,4-dicarboxamide −11.5 1 11 476.56892 5
5 ZINC29590257
8-chloro-7-[(2R,3R,4S,5R)-3-hydroxy-5-
methoxy-6,6-dimethyl-4-(5-methyl-1H-
pyrrole-2-carbonyl)oxyoxan-2-yl]oxy-3-
[[4-hydroxy-3-(3-methylbut-2-
enyl)benzoyl]amino]-4-oxochromen-2-
olate
−11.4 7 8 696.12014 6.1
6 ZINC29590262
8-chloro-7-[(2R,3R,4R,5R)-3-hydroxy-5-
methoxy-6,6-dimethyl-4-(5-methyl-1H-
pyrrole-2-carbonyl)oxyoxan-2-yl]oxy-3-
[[4-hydroxy-3-(3-methylbut-2-
enyl)benzoyl]amino]-4-oxochromen-2-
olate
−11.3 6 8 696.12014 6.1
7 ZINC01568793
2-[4-[4-(1,3-dioxo-2-azaspiro[4.4]nonan-
2-yl)-3-methylphenyl]-2-methylphenyl]-2
azaspiro[4.4]nonane-1,3-dione
−11.1 4 6 484.58608 4.7
8 ZINC01736227
(2S)-5-phenyl-2-[(2S)-5-phenyl-2,3-
dihydro-1,3-benzoxazol-2-yl]-2,3-dihydro-
1,3-benzoxazole
−11.1 2 6 392.4492 6.7
9 ZINC13152284
(2R)-5-phenyl-2-[(2S)-5-phenyl-2,3-
dihydro-1,3-benzoxazol-2-yl]-2,3-dihydro-
1,3-benzoxazole
−11 3 3 392.4492 6.7
10 ZINC18055497 — −11 3 3 479.67574 4.7
11 CID 99478(Natural substrate) — −5.7 7 2 147.12926 —
analysis was performed between energy scores calculated for
all the selected ligand molecules, log P value, and molec-
ular weight (Table 1). We observed a negative correlation
coefficient between energy score and log P value (−0.101)
and between energy score and molecular weight (−0.236).
Statistical supports as evaluated using the correlations clearly
support the fact that the energy score of the ligands is
independent of their molecular weight and logP values, and
energy scoremay dependon interactions or the conformation
of ligands and active site residues.The analysis of the residues
taking part in the interactions in the ten selected ligplot
molecules and the residues involved in the binding of natural
substrate with the cysteine synthase revealed that certain
amino acid residues are found to be conserved in most of the
analyzed interactions (Table 3). A summary of the hydrogen
and the hydrophobic interactions for the top five ligands has
been provided (Table 2), which can be potentially exploited
as lead molecules for the effective development of docking
based targeted drug discovery approaches for T. vaginalis.
4. Conclusion
T. vaginalis is a multidrug resistant pathogen and causes
severe infection in humans which has acquired multidrug
BioMed Research International 13
Table 2: Calculated hydrogen and hydrophobic interactions for the top five best ranking ligands based on Autodock Vina score and Ligplot
interactions.
S. no. ZINC ID IUPAC convention of the ligand Hydrogen bond Hydrophobicinteractions
1 ZINC01690699 1-N,4-N-bis[3-(1H-benzimidazol-2-yl)phenyl]benzene-1,4-dicarboxamide T67, T175, S64
V35, I39, T63, G65,
M86, G89, V90,
T114, A169, T172,
L275 and A277
2 ZINC29590263
8-chloro-7-[(2R,3R,4R,5S)-3-hydroxy-5-methoxy-6,
6-dimethyl-4-(5-methyl-1H-pyrrole-2-carbonyl)oxyoxan-2-
yl]oxy-3-[[4-hydroxy-3-(3-methylbut-2-enyl)benzoyl]amino]-4-
oxochromen-2-olate
N66, T67, T114,
H147, T175
V35, I39, A169,
T172, P197, T202,
K207 and A277
3 ZINC29590259
8-chloro-7-[(2R,3R,4S,5S)-3-hydroxy-5-methoxy-6,6-dimethyl-4-
(5-methyl-1H-pyrrole-2-carbonyl)oxyoxan-2-yl]oxy-3-[[4-
hydroxy-3-(3-methylbut-2-enyl)benzoyl]amino]-4-oxochromen-
2-olate
T67, H147, T175,
L206
4 ZINC04783229 1-N,4-N-bis(3-phenylphenyl)piperazine-1,4-dicarboxamide Q204
V35, G65, T63,
N66, M86, T114,
A169, T172, G205,
L275 and A277
5 ZINC29590257
8-chloro-7-[(2R,3R,4S,5R)-3-hydroxy-5-methoxy-6,6-dimethyl-4-
(5-methyl-1H-pyrrole-2-carbonyl)oxyoxan-2-yl]oxy-3-[[4-
hydroxy-3-(3-methylbut-2-enyl)benzoyl]amino]-4-oxochromen-
2-olate
T63, T67, T114,
T175, L206
V35, K36, I39,
P138, T172, P197,
K207 and A277
Table 3: Composition of active site residues interacting with ligand
and natural substrate.
S. no. Amino acid Position
1. Val 35
2. Ile 39
3. Thr 63
4. Asn 66
5. Thr 67
6. Thr 114
7. His 147
8. Ala 169
9. Gly 171
10. Thr 172
11. Ser 173
12. Thr 175
13. Gly 205
14. Lys 207
15. Ieu 275
16. Ala 277
resistance and cross-resistance against the presently available
drugs, such as metronidazole, nitroimidazoles, and tinida-
zole, which demands the screening of the potential inhibitors
for the effective drug administration. In our study, we selected
cysteine synthase as the most promising drug target for
the drug inhibitor designing. The PDB structure of cysteine
synthase was not available; therefore, it was predicted and
validated with the help of comparative modeling. The virtual
screening for cysteine synthase was carried out against the
NCI database using Autodock Vina, which revealed the top
five candidates in ZINC database and indicated strong bind-
ing affinity for cysteine synthase. We further demonstrated
that inhibitor ZINC01690699, having the minimum energy
score (−13.0 Kcal/Mol) and a log P value of 6, possesses
the highest binding affinity towards the cysteine synthase
and can be a potential putative inhibitor on the basis of
the interactions with residues of the active site of cysteine
synthase. Our conducted research provides a platform for the
experimental verification of the molecule ZINC01690699 as
a potential growth inhibitor of T. vaginalis.
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